Radial Versus Femoral Secondary Access in Patients Undergoing TAVI

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Heart Center Freiburg - Bad Krozingen

About this trial

Severe symptomatic aortic stenosis (AS) with a high gradient is associated with a poor prognosis if not treated with valve replacement. Transcatheter aortic valve implantation has been shown in large randomized trials to be a safe and effective treatment option for patients at low, intermediate, or high risk. Transfemoral access for heart valve replacement is by far the most commonly used approach, as it is relatively easy to control and has a low complication rate compared to other access routes.

The TAVI procedure requires two arterial access points: one with a large lumen for the TAVI prosthesis via the femoral artery, and a smaller second one for a pigtail catheter that guides the TAVI prosthesis into the optimal position. This secondary access is most often via a second artery.

Vascular complications are the most commonly observed complications in transfemoral TAVI and are associated with poorer procedural outcomes.

Recent data suggest that secondary vascular access via the radial artery may contribute to a reduction in vascular complications after TAVI. In patients undergoing coronary angiography and/or percutaneous coronary intervention, radial access has become the preferred strategy due to its proven reduction in vascular complications compared to femoral access. The use of radial access is associated with a lower incidence of vascular complications compared to femoral access.

Recent non-randomized data suggest that radial access may be a safer alternative to traditional femoral access as a secondary arterial access in transfemoral TAVI. However, non-randomized retrospective comparisons are subject to selection bias and underreporting of complications. Therefore, a prospective randomized trial is needed to evaluate the value of radial access for secondary arterial access in patients undergoing transfemoral TAVI.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients scheduled for transfemoral TAVI

Heart team agrees on eligibility of TAVI

Written informed consent

Age > 18 years

Disqualifiers

Non accessible radial arteries as judged by the TAVI team

Non accessible femoral arteries as judged by the TAVI team

Foreseeable problems to achieve primary transfemoral access (hostile access)

Hemodynamic instability or cardiogenic shock

Trial design

Design model

Parallel

Treatments tested in this trial

  • Radial TAVI

    Procedure/Surgery

    patients will recieve the TAVI intervention via radial access

  • femoral TAVI

    Procedure/Surgery

    patients will recieve the TAVI intervention via femoral access

Treatment groups

600 Participants
are divided into 2 treatment groups
Group A: Group 1 RadialActive comparator 1 intervention
Group B: Group 2 femoralActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Vascular and bleeding complications related to the secondary vascular access site

Time frame
30 days

Secondary outcomes

1

Until 30 days after index procedure:

* cardiovascular mortality * non-cardiovascular mortality * mortality related to vascular and bleeding complications * Incidence of new neurological events after randomization * Vascular complications at 30 days * Bleeding complications at 30 days * Incidence of acute kidney injury

Time frame
30 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.